Welcome
Support Centre
24 October 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Metabolic substrate support in left ventricular hypertrophy -HINGE Trial ( Hypertrophy, Insulin, Glucose and Electrolytes Trial)
ISRCTN ISRCTN05758301
DOI 10.1186/ISRCTN05758301
ClinicalTrials.gov identifier
EudraCT number
Public title Metabolic substrate support in left ventricular hypertrophy -HINGE Trial ( Hypertrophy, Insulin, Glucose and Electrolytes Trial)
Scientific title
Acronym N/A
Serial number at source N0265150472
Study hypothesis This study assesses the effect of supplementing naturally-occurring insulin and energy sources (glucose) on heart protection during aortic valve replacement surgery. These treatments have a sound experimental basis for improving outcome. If this improvement is confirmed surgical results could be materially improved. We will be studying heart function, heart muscle energy stores and chemicals which quantify the amount of heart muscle injury.
Lay summary Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Aortic valve replacement
Participants - inclusion criteria Patients eligible for entry into the trial will be consulted and recruited in:
1. Pre-surgical consultation clinic
2. Pre-admission clinic
3. During hospital admission for surgery

Before surgery they will have an echocardiogram/MRI scan to assess left ventricular hypertrophy. 2D directed M-mode echocardiography will be used to determine LV mass using the anatomically-validated cube formula. Consistency will be cross-checked using LV mass quantification from the area-length 2D method. There is no risk associated with transthoracic echocardiography. A subset of subjects will also undergo LV mass assessment using MRS. LV mass will be calculated using serial contiguous short axis TrueFISP cine sequences with 7mm slice thickness and 3mm gap using a 1. 5-Tesla magnet. Analysis will be performed off-line using Siemens ARGOS software. There is no biological risk to MR scanning, although patients with ferromagnetic material within the body have to be excluded (the most common example is that of older cerebral aneurysm clips).
Participants - exclusion criteria Patients with ferromagnetic material within the body.
Anticipated start date 13/08/2004
Anticipated end date 13/08/2008
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants Not provided at time of registration
Interventions On the morning of surgery patients will be randomised to one of two groups. There are 2 groups of patients in this trial, allocated to receive placebo or G.I.K.
1. Group A. receive dextrose 5% run at 0. 75ml/kg/h rounded to the nearest 10 mls/hr starting at sternotomy and finishing 6 hours following release of the aortic cross clamp.
2. Group B: a central intravenous G.I.K. ( 500 ml of 40% glucose 35 units insulin 50 mmols of KC1) run at 0. 75 mis/kg/hr rounded to the nearest 10 mls/hr starting at sternotomy and finishing 6 hours following release of the aortic cross clamp.

Blood for baseline CKMB and cTnI will be drawn for centrifuge and storage and arterial blood gases ( ABC) will be withdrawn for immediate analysis in the anaesthetic room before standard induction using the arterial line routinely inserted before induction of anaesthesia additional) . Alter induction a pulmonary artery balloon flotation catheter will be positioned in the anaesthetic room and the patient then transferred to the operating room ( normal clinical practice or additional). Approximately 40% have such catheters placed routinely for clinical reasons - in the study they will be used in every patient).

Baseline cardiac output studies, pulmonary capillary wedge pressures ( normal clinical practice in the patients or additional).

Surgery will proceed as normal with 1/2 hourly K+ and blood glucose sampling pre-CPB, 20 minutely during CPB and 1 hourly post CPB with protocol based management of blood glucose and potassium. The protocol is based on that used in the DIGAMI study (additional).

Anaesthetic and CPB management will be standardized to control for known factors affecting outcome including pH management, C02 control, re-warming protocols etc. Myocardial protection will be afforded by cold blood cardioplegia. Criteria for the initiation of inotropic or other support will be standardized. Ventilator weaning criteria are standard (normal clinical practice).

During the conduct of the operation in certain cases, the surgeon will place a monitoring cannula in the coronary sinus under direct vision. Such placement is a standard technique for administration of retrograde cardioplegia. In this study it will be placed to undertake oximetric measurement and will be removed at the end of cardiopulmonary bypass. Its insertion and removal are performed under direct vision. The risk associated with this procedure is minimal and should be no greater than the risk of pulmonary flotation catheter insertion (i.e.1:15000 adverse events) (additional).

Myocardial biopsies for will be performed just prior to aortic cross clamp application, just prior to aortic cross clamp release and after 10 minutes of reperfusion. Myocardial diopsies will be snap frozen and stored as mentioned above (additional). In addition a small amount of epicardial and thigh fat and rectus abdominis muscle (pea size) will be removed at approximately the same time. These will be taken from exposed sites through the sternotomy and long saphenous vein harvest sites (additional).
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding University Hospital Birmingham NHS Trust (UK)
NHS R&D Support Funding
Trial website
Publications 1. 2011 results in http://www.ncbi.nlm.nih.gov/pubmed/21200004
Contact name Mr  D  Pagano
  Address Cardiac Surgery
Queen Elizabeth Hospital
  City/town Birmingham
  Zip/Postcode B15 2TH
  Country United Kingdom
Sponsor Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)
  Address The Department of Health
Richmond House
79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)20 7307 2622
  Fax +44 (0)20 7307 2623
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.dh.gov.uk/Home/fs/en
Date applied 30/09/2005
Last edited 28/03/2012
Date ISRCTN assigned 30/09/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.